PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Metsä Board Oyj (METSA.HE)
5.560.02 (-0.36%)
5.56 - 5.56
4.95 - 8.28
45 / 2.4K (Avg.)
-278.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.10%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-6.19%
Negative gross profit growth while STERV.HE is at 0.32%. Joel Greenblatt would examine cost competitiveness or demand decline.
-33.22%
Negative EBIT growth while STERV.HE is at 113.51%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-33.22%
Negative operating income growth while STERV.HE is at 113.51%. Joel Greenblatt would press for urgent turnaround measures.
-59.09%
Negative net income growth while STERV.HE stands at 331.58%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-66.67%
Negative EPS growth while STERV.HE is at 450.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-66.67%
Negative diluted EPS growth while STERV.HE is at 450.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
22.73%
Share change of 22.73% while STERV.HE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
22.73%
Diluted share change of 22.73% while STERV.HE is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
335.14%
Positive OCF growth while STERV.HE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-2119.05%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-28.51%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-28.51%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-31.50%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-88.58%
Negative 10Y OCF/share CAGR while STERV.HE stands at 17.85%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-88.58%
Negative 5Y OCF/share CAGR while STERV.HE is at 14.87%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.90%
Negative 3Y OCF/share CAGR while STERV.HE stands at 40.60%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
108.33%
Net income/share CAGR 1.25-1.5x STERV.HE's 88.37%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
108.33%
5Y net income/share CAGR at 50-75% of STERV.HE's 169.08%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-82.89%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.01%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.05%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-2.65%
Inventory is declining while STERV.HE stands at 0.27%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-15.67%
Negative asset growth while STERV.HE invests at 1.13%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-17.87%
We have a declining book value while STERV.HE shows 2.21%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-29.46%
We’re deleveraging while STERV.HE stands at 1.42%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-0.64%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.